Relmada Therapeutics (NASDAQ:RLMD) Shares Gap Down – Here’s Why

Relmada Therapeutics, Inc. (NASDAQ:RLMD)’s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $7.17, but opened at $6.73. Relmada Therapeutics shares last traded at $6.89, with a volume of 1,882,271 shares traded.

Relmada Therapeutics News Summary

Here are the key news stories impacting Relmada Therapeutics this week:

• Positive Sentiment: 12‑month Phase 2 interim data for NDV‑01 in non‑muscle invasive bladder cancer showed durable complete response rates (76% CR at 12 months overall; 80% CR at 12 months in BCG‑unresponsive patients) with a favorable safety profile and no ≥ Grade 3 treatment‑related adverse events — the company plans to advance NDV‑01 into a Phase 3 registrational program in mid‑2026. Read More.
• Positive Sentiment: Relmada announced an oversubscribed $160.0M PIPE with participation from several prominent life‑science investors (Venrock, RA Capital, OrbiMed, Janus Henderson, etc.), improving near‑term funding visibility for the planned registrational program and other programs. Read More.
• Neutral Sentiment: Market and media reaction: multiple outlets reported large intraday/pre‑market jumps (articles noting 25–61% moves), reflecting investor re‑rating on the data and financing; this coverage likely increased retail and institutional attention and trading volume. Read More.
• Neutral Sentiment: Company investor outreach: management is presenting at the Leerink Partners Global Healthcare Conference this week, providing an opportunity to discuss the data, the Phase 3 plan and financing with investors and analysts. Read More.
• Negative Sentiment: Potential dilution risk: while the $160M PIPE secures funding, it will dilute existing shareholders when executed — a common investor concern that can temper upside after the initial data‑driven rally. Read More.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Relmada Therapeutics in a research note on Wednesday, January 28th. Jefferies Financial Group assumed coverage on shares of Relmada Therapeutics in a research note on Monday, December 22nd. They issued a “buy” rating and a $9.00 price target on the stock. Mizuho raised Relmada Therapeutics from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $1.00 to $10.00 in a research note on Wednesday, November 19th. Lucid Cap Mkts raised Relmada Therapeutics to a “strong-buy” rating in a research note on Monday, March 2nd. Finally, Leerink Partners upgraded shares of Relmada Therapeutics from a “market perform” rating to an “outperform” rating and set a $8.00 target price for the company in a report on Friday, January 23rd. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $9.00.

Relmada Therapeutics Stock Performance

The business has a 50-day simple moving average of $4.18 and a two-hundred day simple moving average of $3.26. The company has a market capitalization of $510.96 million, a price-to-earnings ratio of -3.88 and a beta of 0.72.

Insider Buying and Selling at Relmada Therapeutics

In other news, CFO Maged Shenouda purchased 11,665 shares of the stock in a transaction that occurred on Monday, December 15th. The stock was acquired at an average cost of $4.12 per share, with a total value of $48,059.80. Following the acquisition, the chief financial officer owned 800,000 shares in the company, valued at approximately $3,296,000. This trade represents a 1.48% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 20.70% of the company’s stock.

Hedge Funds Weigh In On Relmada Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Janus Henderson Group PLC acquired a new position in Relmada Therapeutics during the 4th quarter worth $35,041,000. Squadron Capital Management LLC acquired a new position in shares of Relmada Therapeutics during the fourth quarter valued at $32,361,000. Adage Capital Partners GP L.L.C. acquired a new position in shares of Relmada Therapeutics during the fourth quarter worth approximately $20,624,000. Spruce Street Capital LP bought a new position in Relmada Therapeutics during the 4th quarter valued at $19,736,000. Finally, Marshall Wace LLP raised its position in Relmada Therapeutics by 1,072.4% in the fourth quarter. Marshall Wace LLP now owns 3,189,662 shares of the company’s stock worth $15,406,000 after acquiring an additional 2,917,609 shares in the last quarter. 45.24% of the stock is currently owned by hedge funds and other institutional investors.

About Relmada Therapeutics

Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. The company applies a proprietary stereochemical approach to optimized drug candidates, aiming to improve safety, tolerability and efficacy profiles compared with existing treatments. Relmada’s research efforts center on modulation of NMDA receptors to address unmet needs in depression, neuropathic pain and related indications.

Relmada’s lead product candidate, REL-1017 (d-methadone), is being evaluated as a potential rapid-acting and maintenance treatment for major depressive disorder, with clinical studies underway to assess its utility in both acute and long-term settings.